Trials for the tryptophan inhibitor ADI PEG 20 + PD-1 monoclonal antibody Nivolumab + CTLA-4 monoclonal antibody Ipilimumab in patients at high risk of metastatic uveal MM and for the PD-1 monoclonal antibody Spartalizumab + BRAF inhibitors Dabrafenib and Trametinib in patients with unresectable or metastatic BRAF V600 mutation-positive cutaneous MM have also concluded [114,115]. Here, PDCD1 is linked to Miyoshi myopathy.